- uBriGene Biosciences has entered a strategic partnership with Circurna to support process development, scale-up, and GMP manufacturing for circRNA therapeutics.
- The agreement integrates uBriGene’s CDMO capabilities with Circurna’s circular RNA platform to accelerate progression toward clinical studies.
uBriGene Biosciences has announced a strategic partnership with Circurna to support the development and manufacturing of next-generation circular RNA therapeutics. The companies said the agreement will integrate uBriGene’s end-to-end process development, analytical services and GMP production capabilities with Circurna’s proprietary circRNA platform.
Under the collaboration, uBriGene will provide support across process and analytical development, scale-up and GMP manufacturing of both drug substance and drug product. The partnership will also draw on uBriGene’s global manufacturing infrastructure and regulatory expertise to ensure quality and readiness for submissions in multiple jurisdictions.
“Circular RNA offers advantages in stability and translational efficiency. uBriGene’s capabilities in purifying the circRNA to more than 90% purity, and in performing RNA-LNP formulation will accelerate the CMC process for the Circurna product.”
Xiulian Sun, CTO of uBriGene
Circurna’s platform enables programmable circularisation, RNA engineering and targeted delivery to address diseases not currently reachable with conventional RNA technologies. The company said the partnership will help advance its pipeline toward first-in-human studies while establishing a scalable CMC framework. Chief Executive Officer Peter Weinstein said uBriGene’s capabilities in RNA process development, analytics, GMP production and regulatory work make them an aligned partner.
The companies noted that interest in circRNA is growing as it emerges as a next-generation RNA modality. They emphasised that collaboration with a CDMO experienced in complex RNA technologies is essential for progressing early-stage programmes into the clinic.
